文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca dependent allosteric binding site.

作者信息

Dakin Leslie A, Xing Li, Hall Justin, Ding Weidong, Vajdos Felix F, Pelker Jeffrey W, Ramsey Simeon, Balbo Paul, Sahasrabudhe Parag V, Banker Mary Ellen, Choi Won Young, Wright Stephen W, Chang Jeanne S, Curto John M, Davoren Jennifer E, Drozda Susan E, Fennell Kimberly F, Futatsugi Kentaro, Kortum Steve, Lee Katherine L, Liu Shenping, Lovering Frank, Nicki Jennifer A, Trujillo John I, Vincent Fabien, Schnute Mark E

机构信息

Medicine Design, Pfizer Inc, Cambridge, MA, USA.

Medicine Design, Pfizer Inc, Groton, CT, USA.

出版信息

Nat Commun. 2025 May 16;16(1):4579. doi: 10.1038/s41467-025-59919-4.


DOI:10.1038/s41467-025-59919-4
PMID:40379660
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12084562/
Abstract

Peptidylarginine deiminases (PAD1-4) are calcium dependent enzymes responsible for protein citrullination, a post-translational modification converting arginine residues to citrulline. Elevated levels of citrullinated proteins have been associated with rheumatoid arthritis, neurodegenerative diseases, and cancers. Though highly selective PAD4 inhibitors have been described, inhibitors to the broader family currently are limited to covalent substrate analogs. Herein, we describe an allosteric binding pocket common to PAD1-4 suitable for the identification of potent, non-covalent enzyme inhibitors. A ligand-based virtual screen is utilized to identify a PAD4 inhibitor for which surface plasmon resonance confirms target binding but non-competitively with a known PAD4 ligand. We further show through co-crystal structure analysis that the ligand binds PAD4 at an allosteric pocket resulting in stabilization of a catalytically inactive, calcium-deficient enzyme conformation. A ligand designed based on this site potently inhibits all four PAD isozymes and prevents protein citrullination in neutrophils with a broader protein repertoire than observed with a PAD4-selective inhibitor.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/99dedcc8aaa8/41467_2025_59919_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/a18323458fef/41467_2025_59919_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/632557b553a4/41467_2025_59919_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/a6eb014d6448/41467_2025_59919_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/3830b6bcec48/41467_2025_59919_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/fe8eada79472/41467_2025_59919_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/06d9d264c5ca/41467_2025_59919_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/99dedcc8aaa8/41467_2025_59919_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/a18323458fef/41467_2025_59919_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/632557b553a4/41467_2025_59919_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/a6eb014d6448/41467_2025_59919_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/3830b6bcec48/41467_2025_59919_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/fe8eada79472/41467_2025_59919_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/06d9d264c5ca/41467_2025_59919_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8566/12084562/99dedcc8aaa8/41467_2025_59919_Fig7_HTML.jpg

相似文献

[1]
Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca dependent allosteric binding site.

Nat Commun. 2025-5-16

[2]
Peptidylarginine deiminase (PAD): A promising target for chronic diseases treatment.

Int J Biol Macromol. 2024-10

[3]
Protein Arginine Deiminases (PADs): Biochemistry and Chemical Biology of Protein Citrullination.

Acc Chem Res. 2019-3-7

[4]
Structures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design.

Arch Biochem Biophys. 2021-9-15

[5]
Halogen Bonding Increases the Potency and Isozyme Selectivity of Protein Arginine Deiminase 1 Inhibitors.

Angew Chem Int Ed Engl. 2019-8-1

[6]
Revamped role for approved drug: integrative computational and biophysical analysis of saquinavir's peptidyl arginine deiminase 4 inhibition for rheumatoid arthritis.

Biochem J. 2024-10-16

[7]
An interplay of structure and intrinsic disorder in the functionality of peptidylarginine deiminases, a family of key autoimmunity-related enzymes.

Cell Mol Life Sci. 2019-7-24

[8]
Peptidylarginine deiminases 4 as a promising target in drug discovery.

Eur J Med Chem. 2021-12-15

[9]
Discovery of Novel Potential Reversible Peptidyl Arginine Deiminase Inhibitor.

Int J Mol Sci. 2019-5-2

[10]
Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients.

Clin Rheumatol. 2020-3

引用本文的文献

[1]
Ketone body β-hydroxybutyrate-mediated histone β-hydroxybutyrylation upregulates lipolysis and attenuates metabolic syndrome.

Am J Physiol Cell Physiol. 2025-9-1

[2]
Computer-aided repositioning and functional assessment of novel PAD4 inhibitors.

RSC Med Chem. 2025-6-30

本文引用的文献

[1]
Crystal structure of human peptidylarginine deiminase type VI (PAD6) provides insights into its inactivity.

IUCrJ. 2024-5-1

[2]
A quantitative and site-specific atlas of the citrullinome reveals widespread existence of citrullination and insights into PADI4 substrates.

Nat Struct Mol Biol. 2024-6

[3]
Protein citrullination marks myelin protein aggregation and disease progression in mouse ALS models.

Acta Neuropathol Commun. 2022-9-8

[4]
Critical Assessment of State-of-the-Art Ligand-Based Virtual Screening Methods.

Mol Inform. 2022-11

[5]
The Pfizer Crystal Structure Database: An essential tool for structure-based design at Pfizer.

J Comput Chem. 2022-6-5

[6]
Insights into peptidylarginine deiminase expression and citrullination pathways.

Trends Cell Biol. 2022-9

[7]
Structures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design.

Arch Biochem Biophys. 2021-9-15

[8]
Cellular Mechanisms of NETosis.

Annu Rev Cell Dev Biol. 2020-10-6

[9]
Reciprocal regulation of Th2 and Th17 cells by PAD2-mediated citrullination.

JCI Insight. 2019-11-14

[10]
Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix.

Acta Crystallogr D Struct Biol. 2019-10-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索